News & Media
Press Releases
Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism
March 17, 2022
Download a PDF copy of this press release: EN FR Top-line safety and efficacy data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022 …
Amolyt Pharma Announces European Commission Has Granted Orphan Drug Designation to AZP-3601 for the Treatment of Hypoparathyroidism
March 1, 2022
Download a PDF copy of this press release: EN FR Top-line data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022 LYON, France, and …
Amolyt Pharma to Participate at Three Upcoming Investor Conferences
February 11, 2022
Download a PDF copy of this press release: EN FR LYON, France, and Cambridge, MA, February 11, 2022 — Amolyt Pharma, a global company specialized …
Presentations
- All PRESENTATIONS
- AZP-3813
- AZP-3601
- AZP-3404
All PRESENTATIONS
- All PRESENTATIONS
- AZP-3813
- AZP-3601
- AZP-3404
AZP-3601
Living With an “Invisible Disease”: A Qualitative Study With Patients With Hypoparathyroidism
Written by
Dan Hennings
AZP-3601
Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States
Written by
walid
Upcoming events
Hypopara Awareness Day
Date: June 1, 2022
ENDO 2022 – Annual Meeting of the Endocrine Society
Date: June 10 – June 14, 2022 (Atlanta, Georgia)
ASBMR 2022 Annual Meeting
Date: September 9 - 12, 2022 (Austin, TX)
Social Updates
TWITTER
We are pleased to announce the addition of Mark Sumeray, M.D. to our team as #CMO. Dr. Sumeray bring...
Read More »We're looking forward to joining other leaders in the #endocrine space at #ENDO2022. Our oral presen...
Read More »Our #CEO, Dr. Thierry Abribat, was featured in a recent @Pharmashot interview discussing the investi...
Read More »